Journal of Ophthalmology / 2020 / Article / Tab 3

Research Article

Effects of Oral Vitamin B1 and Mecobalamin on Dry Eye Disease

Table 3

Comparison of pre- and posttreatment among the groups.

1 month-baseline2 months–-baseline2 months-1 month
G1G2G3G4G1G2G3G4G1G2G3G4

Signs (mean ± SD)TMH (mm)0.02 ± 0.060.02 ± 0.06−0.01 ± 0.060.02 ± 0.070.03 ± 0.070.01 ± 0.060.01 ± 0.050.00 ± 0.080.01 ± 0.06−0.01 ± 0.060.01 ± 0.08−0.01 ± 0.06
TBUTF (s)0.04 ± 3.490.17 ± 2.350.69 ± 2.040.59 ± 1.760.66 ± 3.791.42 ± 4.261.15 ± 1.570.79 ± 2.740.62 ± 3.391.25 ± 3.420.48 ± 1.860.66 ± 2.54
TBUTA (s)0.46 ± 2.870.22 ± 2.500.74 ± 1.970.43 ± 1.770.62 ± 3.381.62 ± 3.820.97 ± 2.431.37 ± 2.670.16 ± 2.681.40 ± 2.960.02 ± 1.510.82 ± 2.71
CNFD (mm/mm2)2.42 ± 1.75−0.13 ± 1.663.16 ± 1.94ε3.44 ± 3.550.0213.37 ± 2.600.89 ± 1.077.39 ± 3.57ε9.32 ± 3.000.0010.95 ± 1.431.03 ± 1.534.22 ± 2.834.93 ± 3.210.002

Symptoms (mean ± SD, scores)Dryness0.90 ± 2.11−0.58 ± 2.520.28 ± 3.03−1.41 ± 3.64#0.0050.70 ± 2.39−0.45 ± 2.96−0.81 ± 2.37−1.18 ± 2.65#0.028−0.20 ± 2.540.13 ± 2.48−1.81 ± 2.47ε0.23 ± 2.990.015
Foreign body sensation1.18 ± 3.21−0.08 ± 3.27−0.08 ± 3.11−1.19 ± 3.11#0.0211.18 ± 3.380.60 ± 3.16−1.31 ± 3.65−1.50 ± 5.18#0.0110.00 ± 2.650.68 ± 3.12−1.88 ± 3.14ε−0.91 ± 4.250.013
Pain−0.45 ± 2.160.10 ± 3.57−0.83 ± 3.17−1.50 ± 2.510.05 ± 3.430.18 ± 3.46−1.38 ± 3.09−0.91 ± 3.710.50 ± 3.210.08 ± 3.44−0.46 ± 2.450.91 ± 3.50
Burning0.50 ± 3.000.15 ± 3.330.23 ± 2.28−1.03 ± 3.030.30 ± 2.570.68 ± 3.120.12 ± 1.93−0.55 ± 2.44−0.20 ± 3.390.53 ± 2.97−0.46 ± 2.25−0.09 ± 1.23
Watering0.40 ± 2.91−0.03 ± 2.11−0.73 ± 2.410.22 ± 1.560.38 ± 2.250.03 ± 2.790.00 ± 3.010.55 ± 2.22−0.03 ± 2.090.05 ± 3.390.23 ± 3.020.41 ± 1.22
Asthenopia0.80 ± 3.670.48 ± 2.370.35 ± 2.66−0.34 ± 2.720.60 ± 3.880.00 ± 2.31−0.31 ± 2.770.77 ± 2.41−0.20 ± 2.15−0.48 ± 2.54−1.00 ± 3.201.41 ± 2.130.009
Blurred vision−1.35 ± 3.080.35 ± 4.33−0.28 ± 3.49−1.16 ± 2.070.05 ± 3.590.10 ± 3.890.46 ± 1.70−1.32 ± 2.831.40 ± 3.24−0.25 ± 2.851.50 ± 3.48−0.23 ± 1.850.020
Itching−0.25 ± 2.700.10 ± 3.950.25 ± 3.09−0.72 ± 2.560.30 ± 2.521.33 ± 4.37−0.46 ± 3.11−0.82 ± 3.060.55 ± 1.911.23 ± 3.910.23 ± 3.180.32 ± 1.46
Increased secretions−0.20 ± 1.141.13 ± 3.130.05 ± 2.77−0.38 ± 2.550.045−0.03 ± 2.120.85 ± 3.670.54 ± 3.85−0.23 ± 1.900.18 ± 1.91−0.28 ± 2.750.54 ± 2.920.09 ± 1.19
Photophobia0.55 ± 2.230.10 ± 3.68−0.38 ± 1.44−1.09 ± 2.98−0.08 ± 2.37−0.78 ± 3.35−1.08 ± 2.67−0.95 ± 2.21−0.63 ± 1.82−0.88 ± 2.84−0.81 ± 1.880.50 ± 2.94∂∀
Total1.75 ± 13.111.73 ± 17.65−1.13 ± 14.26−8.59 ± 15.46∂#0.0173.38 ± 11.512.53 ± 13.08−4.23 ± 13.60−6.14 ± 15.06#0.0111.63 ± 11.890.80 ± 16.35−3.92 ± 13.112.64 ± 8.94

Satisfaction (mean ± SD, scores)Before−0.57 ± 3.03−0.71 ± 2.35−0.59 ± 4.110.00 ± 3.71−0.63 ± 2.68−0.21 ± 3.48−0.92 ± 3.00−0.13 ± 4.940.21 ± 3.13−0.22 ± 3.84−0.88 ± 2.50−0.13 ± 1.73
After0.46 ± 2.100.17 ± 3.420.63 ± 3.261.38 ± 1.51
Following advice−0.14 ± 0.65−0.28 ± 1.43−0.38 ± 0.72−0.50 ± 0.93
Improvement−0.07 ± 2.680.33 ± 2.440.38 ± 2.930.25 ± 1.58

G1: group 1; G2: group 2; G3: group 3; G4: group 4; TMH: tear meniscus height; TBUTF: tear film breakup time first; TBUTA: tear film breakup time average; CNFD: corneal nerve fiber density. Satisfaction: before: pretreatment satisfaction with ocular surface; after: posttreatment satisfaction with ocular surface; following advice: compliance with the doctor’s advice; improvement: satisfaction with therapeutic effects. values of less than 0.05 were considered statistically significant and are expressed as groups 1 versus 3, #groups 1 versus 4, εgroups 2 versus 3, groups 2 versus 4, and groups 3 versus 4 among the different groups.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.